Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 714 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR Smoking Initiation Shifting from Teens to Young Adults November 6, 2020 Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with... December 6, 2024 EMA Recommends Granting a Marketing Authorisation for Tislelizumab August 4, 2023 Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells October 15, 2019 Load more HOT NEWS 6 of the biggest good news cancer stories of 2021 InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of... Ponatinib Effectively Treats Newly Diagnosed Acute Lymphoblastic Leukemia: The ASCO Plenary... Is Proton Therapy Safer than Traditional Radiation?
